Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management
Giuseppe Curigliano,Daniela Cardinale,Susan Dent,Carmen Criscitiello,Olexiy Aseyev,Daniel J. Lenihan,Carlo M. Cipolla +6 more
Reads0
Chats0
TLDR
In this paper, the authors focus on the common cardiovascular issues that may arise during or after cancer therapy, the detection and monitoring of cardiovascular injury, and the best management principles to protect against or minimize cardiotoxicity during the spectrum of cancer treatment strategies.Abstract:
Answer questions and earn CME/CNE Cancer and heart disease are the leading causes of morbidity and mortality in the industrialized world. Modern treatment strategies have led to an improvement in the chances of surviving a diagnosis of cancer; however, these gains can come at a cost. Patients may experience adverse cardiovascular events related to their cancer treatment or as a result of an exacerbation of underlying cardiovascular disease. With longer periods of survival, late effects of cancer treatment may become clinically evident years or decades after completion of therapy. Current cancer therapy incorporates multiple agents whose deleterious cardiac effects may be additive or synergistic. Cardiac dysfunction may result from agents that can result in myocyte destruction, such as with anthracycline use, or from agents that appear to transiently affect left ventricular contractility. In addition, cancer treatment may be associated with other cardiac events, such as severe treatment-induced hypertension and vasospastic and thromboembolic ischemia, as well as rhythm disturbances, including QTc prolongation, that may be rarely life-threatening. Early and late effects of chest radiation can lead to radiation-induced heart disease, including pericardial disease, myocardial fibrosis, cardiomyopathy, coronary artery disease, valvular disease, and arrhythmias, in the setting of myocardial fibrosis. The discipline of cardio-oncology has developed in response to the combined decision making necessary to optimize the care of cancer patients, whether they are receiving active treatment or are long-term survivors. Strategies to prevent or mitigate cardiovascular damage from cancer treatment are needed to provide the best cancer care. This review will focus on the common cardiovascular issues that may arise during or after cancer therapy, the detection and monitoring of cardiovascular injury, and the best management principles to protect against or minimize cardiotoxicity during the spectrum of cancer treatment strategies. CA Cancer J Clin 2016;66:309-325. © 2016 American Cancer Society.read more
Citations
More filters
Journal ArticleDOI
Reactive Oxygen Species (ROS)-Based Nanomedicine.
Bowen Yang,Yu Chen,Jianlin Shi +2 more
TL;DR: In this article, the intrinsic biochemical properties of reactive oxygen species (ROS) underlie the mechanisms that regulate various physiological functions of living organisms, and they play an essential role in regulating various physiological function.
Journal ArticleDOI
Exercise Guidelines for Cancer Survivors: Consensus Statement from International Multidisciplinary Roundtable
Kristin L. Campbell,Kerri M. Winters-Stone,Joachim Wiskemann,Anne M. May,Anna L. Schwartz,Kerry S. Courneya,David S. Zucker,Charles E. Matthews,Jennifer A. Ligibel,Lynn H. Gerber,G. Stephen Morris,Alpa V. Patel,Trisha F. Hue,Frank M. Perna,Kathryn H. Schmitz +14 more
TL;DR: Enough evidence was available to conclude that specific doses of aerobic, combined aerobic plus resistance training, and/or resistance training could improve common cancer-related health outcomes, including anxiety, depressive symptoms, fatigue, physical functioning, and health-related quality of life.
Journal ArticleDOI
Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations
Giuseppe Curigliano,Daniel J. Lenihan,Michael G. Fradley,Sarju Ganatra,Ana Barac,Anne H. Blaes,Jörg Herrmann,Charles B. Porter,Alexander R. Lyon,Patrizio Lancellotti,Aarti Patel,Jeanne M. DeCara,Joshua D. Mitchell,Eric E. Harrison,Javid Moslehi,Ronald M. Witteles,Maria Grazia Calabrò,Roberto Orecchia,E. de Azambuja,J. L. Zamorano,Ron Krone,Zaza Iakobishvili,Joseph R. Carver,Saro H. Armenian,Bonnie Ky,Daniela Cardinale,Carlo M. Cipolla,Susan Dent,Karin Jordan +28 more
TL;DR: Common CV toxicities related to cancer therapy are defined, along with suggested strategies for prevention, detection and treatment, and guidance regarding prevention, screening, monitoring and treatment of CV toxicity is provided.
Journal ArticleDOI
Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association.
Laxmi S. Mehta,Karol E. Watson,Ana Barac,Theresa M. Beckie,Vera Bittner,Salvador Cruz-Flores,Susan Dent,Lavanya Kondapalli,Bonnie Ky,Tochukwu M. Okwuosa,Ileana L. Piña,Annabelle Santos Volgman +11 more
TL;DR: This document will provide a comprehensive overview of the prevalence of these diseases, shared risk factors, the cardiotoxic effects of therapy, and the prevention and treatment of CVD in breast cancer patients.
Journal ArticleDOI
Noninvasive Cardiac Radiation for Ablation of Ventricular Tachycardia
Phillip S. Cuculich,Matthew R. Schill,Rojano Kashani,Sasa Mutic,Adam Lang,Daniel H. Cooper,Mitchell N. Faddis,Marye J. Gleva,Amit Noheria,Timothy W. Smith,Dennis E. Hallahan,Yoram Rudy,Clifford G. Robinson +12 more
TL;DR: In five patients with refractory ventricular tachycardia, noninvasive treatment with electrophysiology‐guided cardiac radioablation markedly reduced the burden of ventricular gyrations.
References
More filters
Journal ArticleDOI
Cancer statistics, 2015.
TL;DR: The overall cancer death rate decreased from 215.1 (per 100,000 population) in 1991 to 168.7 in 2011, a total relative decline of 22%.
Journal ArticleDOI
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
Edward H. Romond,Edith A. Perez,John Bryant,Vera J. Suman,Charles E. Geyer,Nancy E. Davidson,Elizabeth Tan-Chiu,Silvana Martino,Soonmyung Paik,Peter A. Kaufman,Sandra M. Swain,Thomas M. Pisansky,Louis Fehrenbacher,Leila A. Kutteh,Victor G. Vogel,Daniel W. Visscher,Greg Yothers,Robert B. Jenkins,Ann M. Brown,S. R. Dakhil,Eleftherios P. Mamounas,Wilma L. Lingle,Pamela M. Klein,James N. Ingle,Norman Wolmark +24 more
TL;DR: Tastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide improves outcomes among women with surgically removed HER2-positive breast cancer.
Journal ArticleDOI
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
Martine Piccart-Gebhart,Marion Procter,Brian Leyland-Jones,Aron Goldhirsch,Michael Untch,Ian E. Smith,Luca Gianni,José Baselga,Richard Bell,Christian Jackisch,David Cameron,Mitch Dowsett,Carlos H. Barrios,Günther G. Steger,Chiun-Shen Huang,Martin Andersson,Moshe Inbar,Mikhail Lichinitser,István Láng,U. Nitz,Hiroji Iwata,C Thomssen,Caroline Lohrisch,Thomas M. Suter,Josef Rüschoff,Tamás Süto ý,Victoria Greatorex,Carol Ward,Eleanor McFadden,M. Stella Dolci,Richard D. Gelber +30 more
TL;DR: One year of treatment with trastuzumab after adjuvant chemotherapy significantly improves disease-free survival among women with HER2-positive breast cancer.
Journal ArticleDOI
Recommendations for the evaluation of left ventricular diastolic function by echocardiography
Sherif F. Nagueh,Christopher P. Appleton,Thierry C. Gillebert,Paolo Marino,Jae K. Oh,Otto A. Smiseth,Alan D. Waggoner,Frank A. Flachskampf,Patricia A. Pellikka,Arturo Evangelisa +9 more
TL;DR: The assessment of left ventricular (LV) diastolic function and filling pressures is of paramount clinical importance to distinguish this syndrome from other diseases such as pulmonary disease resulting in dyspnea, to assess prognosis, and to identify underlying cardiac disease and its best treatment.
Journal ArticleDOI
Cancer treatment and survivorship statistics, 2012
Rebecca L. Siegel,Carol DeSantis,Katherine S. Virgo,Kevin Stein,Angela B. Mariotto,Tenbroeck Smith,Dexter L. Cooper,Ted Gansler,Catherine C. Lerro,Stacey A. Fedewa,Chun Chieh Lin,Corinne R. Leach,Rachel S. Cannady,Hyunsoon Cho,Steve Scoppa,Mark Hachey,Rebecca A. Kirch,Ahmedin Jemal,Elizabeth Ward +18 more
TL;DR: Common cancer treatments, survival rates, and posttreatment concerns are summarized and the new National Cancer Survivorship Resource Center is introduced, which has engaged more than 100 volunteer survivorship experts nationwide to develop tools for cancer survivors, caregivers, health care professionals, advocates, and policy makers.
Related Papers (5)
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)
José Luis Zamorano,Patrizio Lancellotti,Daniel Rodriguez Muñoz,Victor Aboyans,Riccardo Asteggiano,Maurizio Galderisi,Gilbert Habib,Daniel J. Lenihan,Gregory Y.H. Lip,Alexander R. Lyon,Teresa López Fernández,Dania Mohty,Massimo F. Piepoli,Juan Tamargo,Adam Torbicki,Thomas M. Suter,Stephan Achenbach,Stefan Agewall,Lina Badimon,Gonzalo Barón-Esquivias,Helmut Baumgartner,Jeroen J. Bax,Héctor Bueno,Scipione Carerj,Veronica Dean,Çetin Erol,Donna Fitzsimons,Oliver Gaemperli,Paulus Kirchhof,Philippe Kolh,Petros Nihoyannopoulos,Piotr Ponikowski,Marco Roffi,Antonio Vaz Carneiro,Stephan Windecker +34 more
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.
Juan Carlos Plana,Maurizio Galderisi,Ana Barac,Michael S. Ewer,Bonnie Ky,Marielle Scherrer-Crosbie,Javier Ganame,Igal A. Sebag,Deborah A. Agler,Luigi P. Badano,Jose Banchs,Daniela Cardinale,Joseph R. Carver,Manuel D. Cerqueira,Jeanne M. DeCara,Thor Edvardsen,Scott D. Flamm,Thomas Force,Brian P. Griffin,Guy Jerusalem,Jennifer E. Liu,Andreia Magalhaes,Thomas H. Marwick,Liza Y. Sanchez,Rosa Sicari,Hector R. Villarraga,Patrizio Lancellotti +26 more